ArticleCureus2025
Spectrum of Fungal Infections in Continuous Ambulatory Peritoneal Dialysis: A 20-Year Retrospective Study From a Tertiary Care Center.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Fungal peritonitis (FP) is a rare but severe complication in patients on continuous ambulatory peritoneal dialysis (CAPD), leading to high mortality. Globally, FP ranges from 1% to 12%, while in India it reaches up to 24%. In the past decades, rare fungi have been identified as the causative agents of FP. The treatment varies depending on the fungi isolated, and it is important to know the species causing infection. The aim of the present study is to analyze the spectrum of fungal pathogens causing CAPD peritonitis. This study highlights a diverse spectrum of fungal pathogens isolated from CAPD patients over 20 years, emphasizing emerging and rare fungi and underscoring the necessity for species-specific antifungal susceptibility data to guide clinical management. Methods This was a retrospective observational study of 20 years (January 2004-December 2023) conducted at a tertiary care center in India. The CAPD fluid samples received in the Microbiology Department were inoculated into Sabouraud Dextrose Agar with chloramphenicol and incubated at 30°C and 37°C for 5-7 days. The yeast isolates were identified by the VITEK-2C system (bioMérieux, Marcy-l'Étoile, France). Identification of the molds was done by slide culture of the colony. Antifungal susceptibility testing (AFST) for yeasts was performed as per Clinical and Laboratory Standards Institute (CLSI) guidelines M27. Rare pathogens were identified by sequencing the internal transcribed spacer (ITS) region of the rDNA. Results A total of 139 CAPD samples were received from 110 patients. Repeat samples were obtained in 29 patients. Yeast was isolated in 65 (59%) of the samples, whereas mold was isolated in 45 (41%) of the cases. Among the yeasts,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.